CANbridge Pharmaceuticals Inc.

SEHK:1228 Stock Report

Market Cap: HK$89.2m

CANbridge Pharmaceuticals Management

Management criteria checks 2/4

CANbridge Pharmaceuticals' CEO is James Qun Xue, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is CN¥9.55M, comprised of 59.8% salary and 40.2% bonuses, including company stock and options. directly owns 9.85% of the company’s shares, worth HK$8.79M. The average tenure of the management team and the board of directors is 2.5 years and 2.8 years respectively.

Key information

James Qun Xue

Chief executive officer

CN¥9.5m

Total compensation

CEO salary percentage59.8%
CEO tenure6.8yrs
CEO ownership9.9%
Management average tenure2.5yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

Nov 14
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28%

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Sep 27
CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Aug 07
Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23
CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

CEO Compensation Analysis

How has James Qun Xue's remuneration changed compared to CANbridge Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥408m

Mar 31 2024n/an/a

-CN¥393m

Dec 31 2023CN¥10mCN¥6m

-CN¥379m

Sep 30 2023n/an/a

-CN¥416m

Jun 30 2023n/an/a

-CN¥453m

Mar 31 2023n/an/a

-CN¥468m

Dec 31 2022CN¥13mCN¥5m

-CN¥483m

Sep 30 2022n/an/a

-CN¥733m

Jun 30 2022n/an/a

-CN¥982m

Mar 31 2022n/an/a

-CN¥1b

Dec 31 2021CN¥10mCN¥4m

-CN¥1b

Sep 30 2021n/an/a

-CN¥1b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥828m

Dec 31 2020CN¥6mCN¥4m

-CN¥846m

Dec 31 2019CN¥10mCN¥3m

-CN¥218m

Compensation vs Market: James Qun's total compensation ($USD1.32M) is above average for companies of similar size in the Hong Kong market ($USD233.03K).

Compensation vs Earnings: James Qun's compensation has been consistent with company performance over the past year.

CEO

James Qun Xue (54 yo)

6.8yrs

Tenure

CN¥9,545,000

Compensation

Dr. James Qun Xue, Ph D., M.B.A., has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serv...

Leadership Team

NamePositionTenureCompensationOwnership
James Qun Xue
Founder6.8yrsCN¥9.55m9.85%
HK$ 8.8m
Qian Ma
General Counsel3.4yrsno datano data
Stella Mao
Vice President of Public Affairs4.8yrsno datano data
Chris Chen
Vice President of Human Resourcesno datano datano data
Gerald F. Cox
Chief Development Strategist & Interim Chief Medical Officer5.3yrsno datano data
Pauline Li
Chief Medical Officerno datano datano data
Rebecca Zhang
Senior Vice President of Regulatory Affairs2.3yrsno datano data
Jeff Kou
Director and Head of Program Management & Clinical Operations2.8yrsno datano data
Fannie Man
Mainland China Commercial Head & GM of Hong Kong and Macau1.3yrsno datano data
Jason West
Head of Global Gene Therapy Researchno datano datano data
Joe Shen
Senior Vice Presidentless than a yearno datano data
Will Wang
Senior Director & Head of Productionno datano datano data

2.5yrs

Average Tenure

Experienced Management: 1228's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Qun Xue
Founder6.8yrsCN¥9.55m9.85%
HK$ 8.8m
James Arthur Geraghty
Independent Non-Executive Director6.3yrsCN¥317.00k0.16%
HK$ 147.0k
Peng Kuan Chan
Independent Non-Executive Director3.4yrsCN¥317.00kno data
Richard Gregory
Independent Non-Executive Director4.6yrsCN¥317.00kno data
Guangping Gao
Member of Strategic Advisory Board4.4yrsno datano data
Mark A. Goldberg
Member of Strategic Advisory Boardno datano datano data
Anthony Amato
Member of Scientific Advisory Board2.3yrsno datano data
Richard Polisson
Member of Scientific Advisory Board2.3yrsno datano data
Lan Hu
Independent Non-Executive Director2.8yrsCN¥320.00kno data
Robert Colvin
Member of Scientific Advisory Board2.3yrsno datano data
Jean Francis
Member of Scientific Advisory Board2.3yrsno datano data
Sushrut Waikar
Member of Scientific Advisory Board2.3yrsno datano data

2.8yrs

Average Tenure

63yo

Average Age

Experienced Board: 1228's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.